The National Institute for Health and Care Excellence (NICE) published guidance on the use of pirfenidone (Esbriet ® , Roche) for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) in 2013. NICE decided to review existing guidance following publication of an additional clinical trial, and invited the manufacturer of pirfenidone to submit evidence of its clinical and cost effectiveness for the treatment of mild to moderate IPF when compared with best supportive care (BSC) or nintedanib; nintedanib was a comparator only for moderate IPF. An independent Evidence Review Group (ERG) critiqued the company submission and this paper summarises their report and subsequent NICE guidance. The key clinical effectiveness evidence was based on three randomised controlled trials (RCTs) and an open-label extension study. Supportive data were provided from two additional RCTs conducted in Japan, while one additional open-label study was included for safety outcomes. Meta-analysis of the three key RCTs found pirfenidone to be effective at reducing disease progression compared with placebo, but statistically significant differences were not identified in all of the RCTs. A statistically significant reduction in all-cause mortality was only demonstrated when pooling data across studies. The treatment effects of pirfenidone and nintedanib were broadly similar, based on an indirect comparison using network meta-analysis, although they have slightly different adverse event profiles. There remains considerable uncertainty in the cost-effectiveness estimates for pirfenidone versus BSC, particularly due to uncertainty regarding the duration of treatment effect and the method used to implement the stopping rule within the economic model.
Introduction
The National Institute for Health and Care Excellence (NICE) is an independent organisation whose responsibilities include providing national guidance to the National Health Service (NHS) in England on health technologies. The NICE Single Technology Appraisal (STA) process usually covers new single health technologies within a single indication, soon after the UK market authorisation [1] . The manufacturer submits evidence on the clinical and cost effectiveness of the technology, including a de novo economic model, and an independent Evidence Review Group (ERG) review this submission. The NICE Appraisal Committee (AC) consider the evidence submitted by the company and the ERG, alongside testimony from experts and other stakeholders in order to develop national recommendations for England reported within a Final Appraisal Determination (FAD). An Appraisal Consultation Document (ACD) is initially produced if the recommendations from the AC are restrictive or additional clarification is required from the manufacturer about their submission. All stakeholders have an opportunity to comment on the ACD before the AC meets again to produce the FAD.
Pirfenidone is effective at reducing disease progression compared with placebo in patients with mild to moderate idiopathic pulmonary fibrosis (IPF).
There is a lack of head-to-head data comparing pirfenidone to nintedanib, but based on an indirect comparison, the treatment effects of pirfenidone and nintedanib appear to be broadly similar, although they have slightly different adverse event profiles.
The estimates of cost effectiveness for pirfenidone versus best supportive care were all above £20,000 per qualityadjusted life-year (QALY) gained and were associated with uncertainty in both the population with mild to moderate IPF and the subgroup with moderate IPF.
The committee did not want to withdraw an existing treatment option for moderate disease, and decided not to make any changes to the existing National Institute for Health and Care Excellence (NICE) guidance as pirfenidone had been considered a reasonably innovative treatment at the time of the previous appraisal and it had not seen any clinical evidence contradictory to that considered previously.
included a consideration of whether to change the guidance for patients with an FVC above 80% predicted and whether to remove the stopping rule [3] . Nintedanib and best supportive care (BSC) were listed as relevant comparators but, based on the recommendations in TA379, nintedanib was listed as a comparator only for the subgroup of patients with a percent predicted FVC of between 50 and 80%. The final scope specified that if evidence allowed, subgroup analysis by disease severity, defined by FVC (such as above and below 80% FVC) and/or DLco, should be considered.
The Independent Evidence Review Group (ERG) Review

Clinical Effectiveness Evidence Provided by the Company
The manufacturer of pirfenidone submitted a systematic review of randomised controlled trial (RCT) evidence comparing pirfenidone with placebo in adults with mild or moderate IPF [9] . The review identified three multicentre international RCTs: ASCEND [10] and the two CAPACITY (Clinical Studies Assessing Pirfenidone in idiopathic pulmonary fibrosis: Research of Efficacy and Safety Outcomes, 1 and 2) [11] studies. ASCEND and CAPACITY 1 compared pirfenidone at the UK licensed dose of 2403 mg/day with placebo, whilst CAPACITY 2 compared pirfenidone at doses of 2403 and 1197 mg/day with placebo. It also identified two multicentre Japanese RCTs (SP2 and SP3), which compared lower doses of pirfenidone that were licensed in Japan but not in the UK [12, 13] . The five trials included more than 1700 patients with IPF. To be included in the key trials, patients had to have a predicted FVC of > 50% and < 90% (ASCEND) or simply > 50% (CAPACITY 1 and 2); approximately 25% of these patients were considered to have mild disease, i.e. predicted FVC of > 80%. The ASCEND and SP3 trials had 52 weeks' follow-up, the CAPACITY trials had 72 weeks' follow-up, and the SP2 trial was terminated early at 36 weeks. All but the ASCEND study had been part of the evidence considered in TA282. The company reported random effects meta-analyses that indicated that, when trial data were pooled, there was a beneficial treatment effect for pirfenidone compared with placebo for FVC, mortality and progression-free survival (PFS) (see Table 1 ).
However, a statistically significant difference (p < 0.05) in favour of pirfenidone was not observed in each individual trial. This was the case for the CAPACITY 1 trial for the binary outcome of a ≥ 10% decline in percent predicted FVC or death (p = 0.440) (see Table 2 ) and for change from baseline in FVC/VC (mL) (p = 0.508) (see Table 3 ), and for the ASCEND trial (p = 0.105) and the pooled CAPACITY trials at 72 weeks (p = 0.315) for all-cause mortality (Table 4) . Similar treatment effects were found in the company's metaanalysis of PFS at 52 weeks (see Table 1 ), but again it should be noted that a statistically significant difference in favour of pirfenidone was not demonstrated in the CAPACITY 1 trial at 72 weeks [hazard ratio (HR) 0.84; 95% confidence interval (CI) 0.58-1.22; p = 0.355].
The company provided subgroup analyses, according to disease severity (mild vs. moderate, with mild being FVC > 80% of predicted), for both PFS and overall survival (OS) when pooling data across ASCEND and CAPACITY 1 and 2. Whilst the treatment-by-subgroup interaction test was not statistically significant for either outcome, the reduction in OS was not statistically significant in the mild subgroup (HR at 72 weeks of 0.90, 95% CI 0.27-2.99; p = 0.8610) but remained statistically significant in the moderate subgroup (HR at 72 weeks of 0.58, 95% CI 0.36-0.94; p = 0.0240). 2 , SP3, SP2) reported data on the change from baseline in DLco, but none found a statistically significant treatment effect compared with placebo for this outcome measure and meta-analysis was not conducted.
For the outcome of acute exacerbation, the definitions used varied across the trials. The ASCEND study reported much higher rates in the control arm (14% in ASCEND vs. 0% and 2% in CAPACITY trials 1 and 2, respectively). A random effects meta-analysis of ASCEND, the CAPACITY The company submitted evidence from one ongoing, non-controlled, open-label extension of the ASCEND and CAPACITY trials (RECAP). The company stated that results were similar to the comparisons reported for the trials. The company also provided non-randomised comparisons of patients who received pirfenidone in the ASCEND and CAPACITY trials against patients who received BSC who were enrolled in registry studies for OS (the HRs are confidential and cannot be reported here).
The company presented safety evidence from ASCEND, CAPACITY 1 and 2, SP3, SP2, RECAP [14] and PIPF-002 [15] , an ongoing open-label, compassionate-use, safety study in US patients with either IPF or secondary pulmonary fibrosis. Adverse events (AEs) of any intensity with the highest frequency across all trials were nausea, rash, dizziness, dyspepsia and anorexia, and these were all relatively frequent compared with placebo (no statistically significant p values for between-group differences were reported, except for IPF). SP3 and SP2 also reported a very high frequency of photosensitivity (much higher than the CAPACITY trials). Similar, albeit slightly higher, frequencies of these and other AEs were found in an integrated population from the RECAP extension study. Meta-analyses of treatment-emergent serious AEs using data from ASCEND, CAPACITY 1 and 2 and SP3 at week 52 showed no difference between the pirfenidone and placebo groups (OR 0.90, 95% CI 0.70-1.15; p value not reported).
In the absence of head-to-head RCTs evaluating nintedanib against pirfenidone the company performed an indirect treatment comparison using Bayesian random effects network meta-analysis (NMA). NMAs were conducted separately for 11 outcomes relevant to the decision problem and key AE outcomes. A total of eight studies [ASCEND, CAPACITY 1 and 2, SP3, INPULSIS 1 and 2, To Improve Pulmonary Fibrosis with BIBF 1120 (TOMORROW) and Prednisone, Azathioprine, and N-Acetylcysteine: A Study That Evaluates Response (PANTHER)] were included but the number of studies contributing to each NMA differed by outcome [10, 11, 13, [16] [17] [18] [19] . Results of the NMA are summarised in Table 5 , and the results of four of these outcomes (OS, PFS, time to treatment discontinuation and acute exacerbations) were used to inform the economic model. Based on the NMA, the treatment effects for pirfenidone were broadly similar to those for nintedanib for all outcomes, with the pairwise treatment effects indicating that neither treatment is statistically significantly more effective. NMA of safety data indicated that pirfenidone is associated with reduced odds of diarrhoea and increased odds of rash as compared to nintedanib. For discontinuation due to AEs and serious cardiac AEs, the treatment effects for pirfenidone were broadly similar to those for nintedanib, with the pairwise treatment effects indicating that neither treatment is associated with more AEs.
Critique and Interpretation of the Clinical Evidence
The company submission (CS) addressed the population specified in the scope and subgroup analyses were provided for patients with an FVC above 80% predicted (described as mild IPF in the CS) and between 50 and 80% predicted (described as moderate IPF in the CS), but no subgroups results were presented by DLco status. The final selection of three trials (ASCEND, CAPAC-ITY 1 and CAPACITY 2) for the main clinical efficacy review was considered appropriate by the ERG, as was the inclusion of the trials from Japan, SP3 and SP2, as supporting evidence. An additional relevant trial was also identified by the ERG and included as supporting evidence: this was a multicentre Chinese trial, which compared pirfenidone plus N-acetylcysteine (NAC) with placebo plus NAC in adult patients with mild or moderate IPF [20] .
The ERG noted that there were between-trial differences across some baseline characteristics in the three key trials (ASCEND, CAPACITY 1 and CAPACITY 2), such as mean FVC or 6MWD at baseline, although subgroup analyses suggested that these and other variables did not influence treatment effect. However, the ERG had some concerns regarding the generalisability of the trial populations. The patients included in the main clinical trials for pirfenidone may not be wholly representative of the population likely to receive pirfenidone in clinical practice as real-life patients often have co-morbidities, more severe disease, take concomitant medications and have a higher mortality risk than those patients enrolled within the clinical trials [21] . Patients with IPF and co-morbid obstructive airway disease were excluded from the three main RCTs, but would be considered for treatment in current practice in the UK provided they have a percent predicted FVC of between 50 and 80%.
Overall, the ERG assessed the potential risk of bias in ASCEND and CAPACITY 1 and CAPACITY 2 to be low across most domains, with the exception of reporting bias and "other bias", which were judged to be "moderate" because of inconsistencies between some of the outcome measures and analyses specified in the trial protocols and those presented in the CS, and because of the possible influence of uncontrolled variables such as rate of disease progression. The supporting trials, SP3, SP2 and Huang et al. [20] , were at a higher or more unclear risk of bias across many domains than the ASCEND and CAPACITY trials.
The ERG also noted that, for FVC outcomes, statistically significant differences were observed in ASCEND and CAPACITY 2 but not in CAPACITY 1. In response to an ERG request to explain the differences between the trials on this outcome, the company stated that "the natural variability in rates of FVC percent predicted decline of this heterogeneous disease" might explain differences in outcomes both within and across trials [22] . This pattern of non-significant differences for CAPACITY 1 was also observed for PFS and one of the functional measures used to define progression (a ≥ 50 m decline in 6MWD or death). The ERG accepted that there were fewer overall deaths in the pirfenidone arms than in the placebo arms of the ASCEND and CAPACITY trials and that, in some pooled analyses, these differences were statistically significant at the 5% level. However, in the meta-analysis of OS from ASCEND, CAPACITY 1 and CAPACITY 2, the ERG noted that the reduction in mortality was lower when including 72-week data from the CAPACITY trials instead of 52-week data. The ERG noted that there appeared to be a markedly increased rate of mortality in the CAPACITY trials between the data reported for 52 weeks and for 72 weeks (see Table 4 ), and the reasons for this were unclear.
The ERG noted how the effect of the "intrinsic variability in rates of FVC decline" [11] might explain differences in some outcomes across trials. Participants in the trials included in the CS were not stratified by rate of progression, so it is possible, for example, that the placebo arm might have had more participants with more rapidly progressing disease than the intervention arm. As a result, the true treatment effect of the intervention relative to placebo is uncertain. This could work either for or against the intervention.
The ERG noted that whilst there is a lack of statistical evidence to support a difference in clinical effectiveness for OS by disease severity, the effect of treatment on OS is more uncertain in the mild subgroup.
The ERG noted that, overall, some AEs were frequent, but that these were generally mild or moderate in severity, and the majority of safety data were from trials with a follow-up of no more than 72 weeks. However, two ongoing studies would address some outstanding issues: RECAP and PIPF-002.
The ERG considered the NMA to be of good methodological quality, and the choice of random effects model was appropriate given the stated concerns in terms of heterogeneity between the studies. The ERG's key concerns were in the use of the earlier 52-week follow-up data for key time-to-event outcomes (all-cause mortality and PFS), rather than the full 72-week data available, and the difference in the treatment effects observed at these two timepoints despite the claim of proportional hazards (PH) over both the observed and unobserved time period.
The definition of PFS used across the pirfenidone trials was not consistent, although, where possible, individual patient data (IPD) were re-analysed to provide results based on a consistent definition. However, this could not be done for all of the trials that contributed to the NMA. The ERG considered that the NMAs that combined data from studies using different PFS definitions should be interpreted with caution. The ERG also noted that the treatment effect for a number of clinically important and patient-reported outcomes was either not statistically significant (DLco and SGRQ) or did not meet the threshold for a clinically important difference (UCSD SOBQ).
Cost-Effectiveness Evidence Provided by the Company
The company submitted a fully executable economic model as part of their submission to NICE [9] . The analysis was undertaken from the perspective of the UK NHS and Personal Social Services (PSS) over a lifetime horizon. The CS presented analyses for three populations: mild to moderate IPF (the intention-to-treat [ITT] trial population); mild IPF (percent predicted FVC > 80%); and moderate IPF (percent predicted FVC between 50 and 80%). BSC was included as a comparator for all three populations but nintedanib was only included as a comparator for the moderate population.
In the company's base case, patients initiating pirfenidone are assumed to discontinue treatment at the rate observed in the trials; therefore, no stopping rule is applied in the base case. The stopping rule defined by NICE which formed the basis for the positive recommendation for pirfenidone and nintedanib is, however, applied to nintedanib in the company's base case. A scenario analysis is also presented where the stopping rule is applied to both nintedanib and pirfenidone. The company's original analysis presented results for a revised PAS that resulted in a reduced discount for pirfenidone relative to the PAS accepted in TA282.
The company's base-case model used three main health states: progression-free, progressed and dead. The progression-free and progressed states were further divided into on and off treatment sub-states. The company's model adopted a cohort-based partitioned survival approach whereby the OS, PFS and discontinuation curves for pirfenidone were extrapolated from the phase III trial data over a lifetime horizon using parametric functions, and these curves were used to determine the proportion of patients residing in each state over time. Treatment effects for PFS and OS were incorporated by applying HRs (BSC vs. pirfenidone and nintedanib vs. pirfenidone) from the NMA, which were based on outcomes at 48 or 52 weeks in the company's base-case analysis. In the company's original base-case analysis these were applied over the whole lifetime irrespective of time on treatment, but sensitivity analyses explored shorter durations of treatment effect.
The company's model used a price year of 2014-2015 and included costs for drug treatments, patient monitoring, AEs, acute exacerbations, lung transplants and end-of-life care. The utility values attached to the health states were estimated by mapping from the SGRQ outcomes collected in the CAPACITY trials to the EQ-5D using a published algorithm.
Based on the company model when incorporating the revised PAS for pirfenidone, the incremental cost-effectiveness ratio (ICER) for pirfenidone versus BSC was £21,387 per quality-adjusted life-year (QALY) gained in the ITT population, £24,187 per QALY gained in the mild subgroup and £21,318 per QALY gained in the moderate subgroup. The results for pirfenidone versus nintedanib when incorporating both the nintedanib PAS and the revised pirfenidone PAS (moderate subgroup) are confidential.
The company presented a series of scenario analyses. The ICERs were mostly sensitive to the assumption regarding the time horizon, the duration over which the treatment effect is assumed to remain constant, the parametric distributions for OS in patients initiating pirfenidone, the treatment effects taken from the NMAs for OS, and the inclusion of stopping rules for pirfenidone and nintedanib.
Critique of the Cost-Effectiveness Evidence and Interpretation
The company's model, which was based on a single point of disease progression, failed to capture the ongoing progressive nature of IPF as patients in the progressed state were assumed not to experience any further quality-of-life decrement from subsequent declines in lung function. The ERG considered that this may have resulted in lifetime QALY gains being overestimated. Furthermore, the company's model assumed that all disease progression is equally detrimental regardless of the starting level of FVC, which was not deemed appropriate following clinical advice. In the company's model acute exacerbations are disconnected from the outcomes of progression and survival and are instead included as a simple cost and utility decrement during each model cycle. Clinical advisors to the ERG suggested that patients who have experienced an exacerbation would usually be considered to have progressed. The ERG therefore considered that the company's model failed to accurately reflect the relationship between acute exacerbations and progression.
When the stopping rule was implemented in the company model, patients were assumed to stop treatment when disease progression occurred. However, because the OS, PFS and discontinuation curves from the trials were modelled independently of each other, treatment discontinuations had no impact on OS. Therefore, the ICERs presented by the company using the stopping rule could represent a lower bound of the true ICER when the stopping rule is implemented in clinical practice, as the lifetime costs of treatment were reduced when the stopping rule was applied in the model, but the incremental QALYs were not reduced by the shorter duration of treatment.
In the company's base case, the treatment effects are estimated from a random effects model including all phase II and III trials using data up to 52 weeks. The ERG considered that (1) the treatment effects estimated using data up to 72 weeks are more appropriate and consistent with the company's assumption of PH; and (2) SP3 should be excluded from the base case as this is a different (Japanese) population with a different dose and statistical adjustments were required as HRs were not reported. The ERG further considered that the CODA sample estimated from the NMA should be used in the economic model instead of the median HR.
The ERG considered that it was overly optimistic to assume that the treatment effects estimated during the trials using the PH assumption would be expected to hold over the patient's entire lifetime irrespective of the duration of treatment.
The ERG noted that the Weibull and Gompertz distributions provided a similar fit to the observed OS but different long-term extrapolations. The ERG considered the Gompertz distribution provided a more realistic long-term extrapolation for OS than the Weibull distribution which was used in the company base case.
The ERG further observed that there was a discrepancy between the model's prediction of OS for patients initiating BSC and the observed trial data for OS in patients who were randomised to placebo. The CS did not comment on this discrepancy and instead focused on a comparison of the model prediction with registry data for patients receiving BSC, even though the registry data did not match the trial data for patients randomised to placebo.
Additional Work Undertaken by the ERG
A number of analyses were undertaken by the ERG which informed the ERG's preferred base case. The main changes within the ERG's preferred base case were:
• use of treatment effects estimated from the NMA from the CODA samples of the predictive distributions, using data up to 72 weeks, excluding SP3; • exploration of different durations for the extrapolation of the treatment effect (2 years and entire model duration); • presentation of results both with and without the stopping rule (see concerns described earlier in this section regarding company's implementation of the stopping rule); • use of the Gompertz distribution for OS (rather than the Weibull); • capping utility estimates for individuals at a maximum of 1.0;
• adjustment of utility by age;
• inclusion of the costs associated with end-of-life care for all patients irrespective of the cause of death; • amendments to dose reductions/interruptions assumed in the company's model for pirfenidone and nintedanib; and • amendment of minor programming errors in the economic model.
The ERG's preferred base case was presented as a range to reflect the uncertainty regarding the duration of treatment effect and the impact of the stopping rule. In each population, the lower range of the ICER incorporated a lifetime treatment effect and included the stopping rule and the upper range of the ICER incorporated a 2-year treatment effect but excluded the stopping rule. For the ITT population the ICERs incorporating the PAS ranged from £27,124 to £115,751 per QALY gained. For the mild population (percent predicted FVC > 80%) the ICERs incorporating the PAS ranged from £31,722 to £186,260 per QALY gained. For the moderate population (percent predicted FVC 50-80%), the ICERs for pirfenidone versus BSC ranged from £27,432 to £104,915 per QALY gained when incorporating the PAS.
In response to a request from the committee, the ERG also provided ICERs for two additional exploratory analyses. The first updated the efficacy estimates in the model to incorporate the results of the NMA when including SP3 and the second included the stopping rule for nintedanib but not for pirfenidone. Both analyses implemented these changes within the model previously used to generate the ERG-preferred base-case ICERs.
Conclusions of the ERG Report
The trials have some issues with generalisability. There is some evidence to support a statistically significant reduction in the decline in percent predicted FVC compared with placebo, but a statistically significant treatment effect was not demonstrated in one of the trials (CAPACITY 1), which weakens the strength of the evidence for this outcome. The available evidence suggests that there is a statistically significant reduction in all-cause mortality for pirfenidone compared with placebo, but there remains uncertainty regarding whether the size of the treatment benefit for OS is constant over time due to variation in the treatment effect estimated using data from 52 and 72 weeks. The safety evidence was generally at low risk of bias but was limited, and questions remain over AE rates in the long-term.
The subgroup analyses by disease severity (percent predicted FVC 50-80% vs. > 80%) presented by the company for the outcomes of PFS and OS were not sufficient to support the use of subgroup-specific treatment effects according to disease severity.
Based on the NMA, the treatment effects for pirfenidone were broadly similar to those for nintedanib for all outcomes, with the pairwise treatment effects indicating that neither treatment is statistically significantly more effective. The NMA incorporating data up to 72 weeks was preferred by the ERG as it includes all of the relevant evidence and is consistent with the company's assumption regarding PH during the observed period.
The company's model did not incorporate the stopping rule in an appropriate manner and the analyses incorporating the stopping rule are likely to overestimate the benefits of pirfenidone compared with BSC. There remains considerable uncertainty in the cost-effectiveness estimates for pirfenidone versus BSC due to uncertainty regarding the duration of treatment effectiveness beyond the trial period. The company's model fails to capture the progressive nature of the disease because it only allowed a single progression and assumed a constant utility in the progressed state, but it is unclear what effect this has had on the ICER.
Draft Guidance in the Appraisal Consultation Document
The committee concluded that, when using the reduced discount in the revised PAS, the most plausible ICERs for pirfenidone versus BSC were above the range that could be considered cost effective. However, in NICE's previous guidance on pirfenidone, the drug was regarded as cost effective for patients with an FVC between 50 and 80% predicted when applying the original PAS. The committee recommended that no changes be made to the original guidance in TA282 in the ACD.
Additional Evidence Submitted by the Company in Response to the Appraisal Consultation Document
In response to the ACD, the company provided revised cost-effectiveness analyses [23] . These were based on the ERG's adaptation of the company's model with the following changes:
• no comparison against nintedanib was presented;
• the discount from the original PAS from TA282 was applied; • treatment effect was varied from 8 years to lifetime (graphical results were provided from 2 years to lifetime); • an additional subgroup analysis was presented for patients with percent predicted FVC ≥ 50% and < 90%; • in addition to the ERG's preferred parametric curve (the Gompertz), the company presented results for two alter-native methods for extrapolating OS: the Weibull and a weighted parametric model; and • the model was populated with CODA samples for the HR for OS at 72 weeks generated by the company using the posterior distribution from the company's original NMA instead of the predictive distribution.
ERG's Critique of the Additional Evidence Submitted
The company had not provided any analysis of clinical effectiveness for the population with percent predicted FVC ≥ 50% and < 90% and, therefore, it was not possible for the ERG to assess the validity of the company's claim that "there is no evidence of a treatment-interaction when the FVC < 90% subgroup is explored". The ERG did not agree with the company's argument that a subgroup analysis for patients with FVC < 90% predicted was justified on the basis that the majority of evidence from the ASCEND and CAPACITY trials was from patients with predicted FVC below 90%. The ERG did not agree with the methods used to generate the weighted parametric curve and considered that the weighted survival curve estimated by the company had limited credibility. The ERG was not convinced that the Weibull curve provided a more plausible extrapolation of OS than the Gompertz curve based on the company's comparison of survival estimates from the INOVA registry data with survival estimates projected by the different parametric curves. The ERG was also not convinced that the data from the INOVA registry could be used to justify a constant treatment effect over 8 years and concluded that there was considerable uncertainty regarding whether the treatment effect observed in the trials persists up to 8 years or beyond. The ERG re-ran the company's analyses using the ERG's original NMA methods (i.e. using the predictive distribution) but having excluded the nintedanib trials and included SP3 (based on the committee's conclusions in the ACD) and found that this had minimal impact on the costeffectiveness estimates.
The company's response to the ACD had argued that there was no difference in the efficacy of pirfenidone by baseline percent predicted FVC and the data from the trial populations should be assessed in their entirety. The ERG considered it reasonable to consider separately the cost effectiveness of pirfenidone in patients with percent predicted FVC ≥ 80% versus those with percent predicted FVC < 80% as there was some evidence from Albera et al. [24] that prognosis differed in these groups, and this difference justified considering whether the cost effectiveness was consistent across the subgroups.
Key Methodological Issues
The partitioned survival approach adopted in the company's model meant that the outcomes of OS, PFS and discontinuation were modelled independently of each other; this effectively assumes that treatment discontinuations, either following disease progression or for other reasons, do not affect OS. Such an approach can be appropriate in situations where treatment discontinuation in clinical practice is likely to follow that observed in the trials and the aim of the model is simply to extrapolate QALY gains beyond the trial period. However, in this case the company needed to incorporate a stopping rule which was not applied in the trials. This required some assumptions to be made regarding the impact on clinical outcomes of patients discontinuing treatment according to the stopping rule. Whilst clinical advisors to the ERG commented that it is hard in this case to understand the relationship between treatment discontinuation and clinical outcomes, the ERG does not believe the company's assumption that there is no relationship between treatment duration and treatment outcomes to be plausible. The ERG considered that the use of a partitioned survival modelling approach was therefore not appropriate in this case.
The company's base-case model appeared to be based on two contradictory positions regarding the PH assumption for PFS and OS. On the one hand, the CS argued that the PH assumption was supported by the trial evidence, and this was used to support the use of a constant HR which was applied over the whole model timeframe. On the other hand, the company argued that the NMA should use only data up to 52 weeks because there are no data to support an assumption of PH for nintedanib versus placebo beyond 52 weeks. The ERG considered that including data up to 72 weeks was consistent with the company's assumption that PHs hold during and beyond the trial period. However, the ERG also noted that the observed reduction in treatment effect between 52 and 72 weeks would not be expected under the PH assumption. The ERG's exploratory analyses demonstrated the importance of exploring alternative assumptions regarding the extrapolation of the treatment effect beyond the trial period. This is particularly important in disease areas where the prognosis is heterogeneous and the mechanism of treatment is not fully understood, making it hard to judge whether a PH assumption beyond the treatment period is reasonable.
NICE Guidance
The committee recommended no change to the existing NICE guidance that recommended pirfenidone as an option for treating IPF in adults only if:
• the person has a FVC between 50 and 80% predicted;
• the company provides pirfenidone with the discount agreed in the PAS; and • treatment is stopped if there is evidence of disease progression (an absolute decline of ≥ 10% in predicted FVC within any 12-month period).
It should be noted that the PAS referred to in the recommendations was the original PAS from TA282 and not the revised PAS proposed in the CS.
The company submitted an appeal against the first FAD (released in September 2016) in which it was claimed that the committee had failed to take into account the totality of the data with respect to "adults with mild to moderate idiopathic fibrosis" (i.e. the population covered by the licensed and specified in the scope) and the committee should not have considered the subgroup with FVC between 80 and 90% of predicted as a relevant population for decision-making. This appeal point was upheld because the Appeal Panel considered that the committee had acted unfairly because they had not demonstrated in the September 2016 FAD that they had considered the whole population as defined in the scope as one population before considering any subgroups, and their use of subgroups, based on the reasoning presented in the September 2016 FAD, was unreasonable. The Appeal Panel also upheld a separate appeal point that the committee's assessment of clinical effectiveness was perverse because the FAD had stated both that "it was not clear whether pirfenidone was more, less or equally effective in the group with FVC above 80% predicted" and that it was "more likely to be less effective" in this group. The Appeal Panel concluded that the AC's assessment of the clinical effectiveness of pirfenidone in any subgroups should be clearly documented, including any uncertainty in the available evidence. The committee met following the appeal decision and addressed the points upheld by the Appeal Panel. The FAD was revised to reflect the committee's discussion, but the recommendations for pirfenidone were unchanged. Although this second FAD was subject to an appeal, the appeal was dismissed on all grounds and the committees' recommendations remained unchanged in the final guidance. Here we summarise some of the committee's key considerations that supported the recommendations in the final guidance.
The committee recognised that the recommendation for nintedanib in TA379 was based on the comparison of nintedanib with pirfenidone, rather than nintedanib with BSC. The committee concluded that it was therefore more appropriate for decision-making to compare pirfenidone only with BSC.
The committee concluded that patients with an FVC above 80% predicted were under-represented in the clinical trials and that the trial evidence was most generalisable to patients with an FVC of up to 90% predicted. However, the committee agreed to accept that pirfenidone has the same relative effectiveness in patients with an FVC above 80% predicted and in patients with an FVC of 80% predicted or less.
The committee concluded that the company's evidence did not conclusively show that patients continue to benefit from pirfenidone after disease progression. However, the committee recognised the comments from clinical experts that some patients may benefit after disease progression. It concluded it was appropriate to consider cost-effectiveness analyses with and without the stopping rule. However, the committee concluded that the analyses that included a stopping rule were associated with uncertainty as the ERG and company expressed differing views in the meeting on whether the implementation of the stopping rule would under-or over-estimate the ICERs.
The committee agreed to take both the Weibull and Gompertz curves into account in its decision-making because they considered that the true risk of death might lie between the two distributions, but closer to the Gompertz distribution. The committee concluded that the evidence did not justify assuming a constant mortality benefit for 8 years, but it was reasonable to assume a constant benefit up to 5 years.
The committee concluded that the ICERs for pirfenidone versus BSC that matched their preferred assumptions for the population specified in the marketing authorisation (i.e. FVC above 50% predicted), when including the stopping rule and assuming a 5-year treatment effect, were between £25,706 and £28,870 per QALY gained depending on whether the Gompertz or Weibull survival curves were used. They further concluded that these ICERs were uncertain for the following reasons:
• the modelled population did not include as many patients with an FVC above 80% predicted as expected in NHS practice and this may increase the ICER; • the impact of the stopping rule on the ICER was uncertain; and • there was still uncertainty about how long the survival benefit of pirfenidone would last (it could be less than 5 years).
The committee concluded that pirfenidone could not be considered a cost-effective use of NHS resources for adults with mild to moderate idiopathic fibrosis because the ICERs were above £20,000 per QALY gained and were associated with some uncertainties that had the potential to substantially increase the ICER.
The committee concluded that the most plausible ICERs for the subgroup with a starting FVC of between 50 and 80% predicted were between £24,933 and £27,780 per QALY gained (for Weibull and Gompertz survival curves, respectively) and were also subject to uncertainties that may substantially increase the ICER. However, the committee understood that pirfenidone had been considered reasonably innovative at the time of the previous appraisal, and it had not seen any clinical evidence contradictory to that considered previously. The committee therefore decided not to change this recommendation and withdraw an existing treatment option for patients with moderate disease, despite the relatively high ICERs.
The committee were aware that removing the stopping rule increased the ICERs and therefore concluded that pirfenidone could not be considered cost effective without the stopping rule given that the ICERs with the stopping rule were already in the £20,000 to £30,000 per QALY gained range and associated with uncertainty.
Conclusions
Whilst the ASCEND study has provided additional evidence supporting the clinical effectiveness of pirfenidone in patients with mild to moderate IPF, there remains considerable uncertainty as to whether the benefits observed in the trial will persist in the long-term, and the estimates of cost effectiveness were particularly sensitive to this uncertainty. The implementation of the stopping rule based on disease progression within an economic model based on partitioned survival was problematic and resulted in additional uncertainty in the ICERs for these analyses but the committee concluded that pirfenidone was not cost effective without the stopping rule.
